Swedish Orphan Biovitrum AB (publ)

General ticker "BIOVF" information:

  • Sector: Health Care
  • Industry: Drug Manufacturers - Specialty & Generic
  • Capitalization: $11.4B (TTM average)

Swedish Orphan Biovitrum AB (publ) follows the US Stock Market performance with the rate: 33.7%.

Estimated limits based on current volatility of 3.1%: low 43.50$, high 46.09$

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2025-12-31 to 2027-12-31

  • 2025-12-31 to 2026-12-31 estimated range: [28.65$, 43.47$]
  • 2026-12-31 to 2027-12-31 estimated range: [27.77$, 42.68$]

Similar symbols

Short-term BIOVF quotes

Long-term BIOVF plot with estimates

Financial data

YTD 2023-12-31 2024-12-31 2025-12-31
Operating Revenue SEK22,123.00MM SEK26,027.00MM SEK28,167.16MM
Operating Expenses SEK18,057.00MM SEK20,402.00MM SEK20,139.35MM
Operating Income SEK4,066.00MM SEK5,625.00MM SEK8,027.81MM
Non-Operating Income SEK-1,112.00MM SEK-1,218.00MM SEK-7,993.90MM
Interest Expense SEK1,111.00MM SEK1,239.00MM SEK828.92MM
R&D Expense SEK2,796.00MM SEK3,538.00MM SEK3,240.85MM
Income(Loss) SEK2,954.00MM SEK4,407.00MM SEK33.91MM
Taxes SEK546.00MM SEK528.00MM SEK-440.89MM
Profit(Loss)* SEK2,409.00MM SEK3,885.00MM SEK476.80MM
Stockholders Equity SEK33,867.00MM SEK40,286.00MM SEK37,622.39MM
Inventory SEK3,874.00MM SEK4,159.00MM SEK5,114.14MM
Assets SEK74,027.00MM SEK75,444.00MM SEK67,264.84MM
Operating Cash Flow SEK4,470.00MM SEK7,388.00MM SEK8,542.52MM
Capital expenditure SEK4,943.00MM SEK3,005.00MM SEK39.90MM
Investing Cash Flow SEK-21,904.00MM SEK-3,091.00MM SEK-4,283.23MM
Financing Cash Flow SEK17,012.00MM SEK-4,001.00MM SEK-4,312.16MM
Earnings Per Share** SEK7.39 SEK11.37 SEK1.38

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.